Facing the unique challenges of dyskinesias in Parkinson's disease

Future Neurology

Volumn 7, Issue 2, 2012, Pages 127-143

  Homayoun, Houman ^a   Goetz, Christopher G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

basal ganglia; deep brain stimulation; diphasic dyskinesia; dopamine; dyskinesia rating scale; glutamate; OFF state dystonia; peak dose dyskinesia; placebo effect

Indexed keywords

ADENOVIRUS VECTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; ETIRACETAM; GLUTAMATE DECARBOXYLASE; LEVODOPA; NEURTURIN;

BASAL GANGLION; BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INFECTION; CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; DRUG MECHANISM; DYSKINESIA; EPIDEMIOLOGICAL DATA; HUMAN; IATROGENIC DISEASE; NEUROPHARMACOLOGY; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PLACEBO EFFECT; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84858255167     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.4     Document Type: Review

References (110)

1. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur. J. Neurol. 12(12), 956-963 (2005). (Pubitemid 41820050)
2. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. 7(2), 117-124 (1992).
3. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47(4 Suppl. 1), S2-S9 (2000).
4. Lewitt PA. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. Mov. Disord. 13(4), 731-734 (1998).
5. Weiner WJ, Goetz CG, Nausieda PA, Klawans HL. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann. Intern. Med. 88(3), 327-331 (1978). (Pubitemid 8287464)
6. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov. Disord. 22(10), 1379-1389 (2007). (Pubitemid 47280623)
7. Rice JE, Antic R, Thompson PD. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Mov. Disord. 17(3), 524-527 (2002). (Pubitemid 36040966)
8. Ruzicka E, Zarubova K, Nutt JG, Bloem BR. 'Silly walks' in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias. Mov. Disord. 26(9), 1782-1784 (2011).
9. Fernandez HH, Friedman JH. Punding on l-dopa. Mov. Disord. 14(5), 836-838 (1999).
10. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20(Suppl. 11), S11-S16 (2005). (Pubitemid 40846906)
11. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov. Disord. 9(1), 2-12 (1994). (Pubitemid 24022609)
12. Rascol O, Fabre N, Brefel-Courbon C, Ory-Mange F, Perez-Lloret S. Dyskinesias. In: The Encyclopedia of Movement Disorders. Kompoliti K, Verhagen Metman L (Eds). Academic Press, CA, USA, 350-361 (2010).
13. Eriksen N, Stark AK, Pakkenberg B. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta. J. Neural Transm. Suppl. (73), 203-213 (2009).
14. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol. 8(12), 1172-1178 (2009).
15. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 16(8), 490-497 (2010).
16. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123(Pt 11), 2297-2305 (2000).
17. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351(24), 2498-2508 (2004).
18. Hauser RA, Mcdermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch. Neurol. 63(12), 1756-1760 (2006). (Pubitemid 44925085)
19. Kostic VS, Marinkovic J, Svetel M, Stefanova E, Przedborski S. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur. J. Neurol. 9(1), 9-14 (2002).
20. Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson's disease. Eur. J. Neurol. 16(4), 450-456 (2009).
21. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur. J. Neurol. 15(5), 493-496 (2008). (Pubitemid 351499195)
22. Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual. Life Res. 9(1), 87-100 (2000). (Pubitemid 30670652)
23. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2(8), 577-588 (2001). (Pubitemid 33679831)
24. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 34(1), 193-196 (1989). (Pubitemid 20008903)
25. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann. Neurol. 39(5), 561-573 (1996). (Pubitemid 26143594)
26. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13(7), 290-296 (1990). (Pubitemid 20193461)
27. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7), 1819-1833 (2007). (Pubitemid 47343795)
28. Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 72(Suppl. 7), S32-S38 (2009).
29. De La Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127(Pt 12), 2747-2754 (2004). (Pubitemid 39627382)
30. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67(9), 1612-1617 (2006). (Pubitemid 44747932)
31. De La Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann. Neurol. 49(3), 298-303 (2001). (Pubitemid 32202782)
32. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 1046(1-2), 230-233 (2005). (Pubitemid 40775894)
33. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131(Pt 1), 120-131 (2008).
34. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445(7128), 643-647 (2007). (Pubitemid 46232883)
35. Picconi B, Paille V, Ghiglieri V, et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol. Dis. 29(2), 327-335 (2008).
36. Picconi B, Bagetta V, Ghiglieri V, et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134(Pt 2), 375-387 (2011).
37. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9(9), 665-677 (2008).
38. Oh JD, Chase TN. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 23(1-3), 133-139 (2002).
39. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 20(8), 919-931 (2005). (Pubitemid 41419505)
40. Dunah AW, Wang Y, Yasuda RP, et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57(2), 342-352 (2000). (Pubitemid 30084511)
41. Gardoni F, Ghiglieri V, Luca M, Calabresi P. Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. Prog. Brain Res. 183, 169-182 (2010).
42. Deutch AY. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease. J. Neural. Transm. Suppl. 70, 67-70 (2006). (Pubitemid 44622181)
43. Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9(2), 251-259 (2006). (Pubitemid 43164549)
44. Alexander GE, Delong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9, 357-381 (1986). (Pubitemid 16055790)
45. Magnin M, Morel A, Jeanmonod D. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience 96(3), 549-564 (2000). (Pubitemid 30136320)
46. Starr PA, Rau GM, Davis V, et al. Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque. J. Neurophysiol. 93(6), 3165-3176 (2005). (Pubitemid 40720899)
47. Sterio D, Beric A, Dogali M, Fazzini E, Alfaro G, Devinsky O. Neurophysiological properties of pallidal neurons in Parkinson's disease. Ann. Neurol. 35(5), 586-591 (1994). (Pubitemid 24153842)
48. Lee JI, Verhagen Metman L, Ohara S, Dougherty PM, Kim JH, Lenz FA. Internal pallidal neuronal activity during mild drug-related dyskinesias in Parkinson's disease: decreased firing rates and altered firing patterns. J. Neurophysiol. 97(4), 2627-2641 (2007). (Pubitemid 46557697)
49. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchison WD, Lozano AM. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J. Neurophysiol. 86(1), 249-260 (2001). (Pubitemid 32623230)
50. Merello M, Balej J, Delfino M, Cammarota A, Betti O, Leiguarda R. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Mov. Disord. 14(1), 45-49 (1999). (Pubitemid 29224675)
51. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov. Disord. 18(4), 357-363 (2003). (Pubitemid 36527275)
52. Lalo E, Thobois S, Sharott A, et al. Patterns of bidirectional communication between cortex and basal ganglia during movement in patients with Parkinson disease. J. Neurosci. 28(12), 3008-3016 (2008). (Pubitemid 351442283)
53. Wingeier B, Tcheng T, Koop MM, Hill BC, Heit G, Bronte-Stewart HM. Intra-operative STN DBS attenuates the prominent beta rhythm in the STN in Parkinson's disease. Exp. Neurol. 197(1), 244-251 (2006). (Pubitemid 41819089)
54. Alonso-Frech F, Zamarbide I, Alegre M, et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain 129(Pt 7), 1748-1757 (2006). (Pubitemid 43999408)
55. Bronte-Stewart H, Barberini C, Koop MM, Hill BC, Henderson JM, Wingeier B. The STN beta-band profile in Parkinson's disease is stationary and shows prolonged attenuation after deep brain stimulation. Exp. Neurol. 215(1), 20-28 (2009).
56. Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol. Dis. 26(2), 452-463 (2007). (Pubitemid 46561343)
57. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 9(6), 762-767 (2003). (Pubitemid 36749227)
58. Berthet A, Bezard E. Dopamine receptors and l-dopa-induced dyskinesia. Parkinsonism Relat. Disord. 15(Suppl. 4), S8-S12 (2009).
59. Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox. Res. 5(1-2), 139-146 (2003).
60. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54(8), 1589-1595 (2000). (Pubitemid 30226801)
61. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov. Disord. 15(1), 3-8 (2000). (Pubitemid 30037981)
62. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 14(3), 404-416 (2003). (Pubitemid 37543519)
63. Schneider JS, Gonczi H, Decamp E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain Res. 990(1-2), 38-44 (2003). (Pubitemid 37244059)
64. Koprich JB, Fox SH, Johnston TH, et al. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Mov. Disord. 26(7), 1225-1233 (2011).
65. Foltynie T, Cheeran B, Williams-Gray CH, et al. BDNF Val66Met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 80(2), 141-144 (2009).
66. Hashimoto T, Tada T, Nakazato F, et al. Abnormal activity in the globus pallidus in off-period dystonia. Ann. Neurol. 49(2), 242-245 (2001). (Pubitemid 32158000)
67. Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery 52(6), 1358-1370; discussion 1370-1373 (2003).
68. Van Der Stelt M, Fox SH, Hill M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19(9), 1140-1142 (2005). (Pubitemid 40946444)
69. Fox SH, Katzenschlager R, Lim S, et al. Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. (Suppl. 26), S2-S41 (2011).
70. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62(3), 381-388 (2004). (Pubitemid 38200847)
71. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin. Neuropharmacol. 27(5), 245-256 (2004). (Pubitemid 39447222)
72. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 20(2), 151-157 (2005). (Pubitemid 40361117)
73. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5(8), 677-687 (2006). (Pubitemid 44081890)
74. Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr. Med. Res. Opin. 27(5), 907-919 (2011).
75. Waters C. Other pharmacological treatments for motor complications and dyskinesias. Mov. Disord. 20(Suppl. 11), S38-S44 (2005). (Pubitemid 40846910)
76. Stocchi F. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S68-S71 (2009).
77. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann. Neurol. 68(1), 18-27 (2010).
78. Riddle LR, Kumar R, Griffin SA, Grundt P, Newman AH, Luedtke RR. Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats. Neuropharmacology 60(2-3), 284-294 (2011).
79. Verhagen Metman L, Del Dotto P, Natte R, Van Den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51(1), 203-206 (1998). (Pubitemid 28345384)
80. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54(8), 1589-1595 (2000). (Pubitemid 30226801)
81. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 6(10), 787-798 (2005). (Pubitemid 41679241)
82. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 26(7), 1243-1250 (2011).
83. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68(1), 45-50 (2007). (Pubitemid 46058551)
84. Morissette M, Dridi M, Calon F, et al. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov. Disord. 21(1), 9-17 (2006). (Pubitemid 43273744)
85. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov. Disord. 25(10), 1437-1443 (2010).
86. Hill MP, Brotchie JM, Crossman AR, et al. Levetiracetam interferes with the dopa priming process in MPTP-lesioned drug-naive marmosets. Clin. Neuropharmacol. 27(4), 171-177 (2004). (Pubitemid 39121729)
87. Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 26(2), 264-270 (2011).
88. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. Neurotrophic factor therapy for Parkinson's disease. Prog. Brain Res. 184, 237-264 (2010).
89. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73(20), 1662-1669 (2009).
90. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9(12), 1164-1172 (2010).
91. Lewitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10(4), 309-319 (2011).
92. Vitek JL, Bakay RA, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann. Neurol. 53(5), 558-569 (2003). (Pubitemid 36529429)
93. Metman LV, O'leary ST. Role of surgery in the treatment of motor complications. Mov. Disord. 20(Suppl. 11), S45-S56 (2005). (Pubitemid 40846911)
94. Foltynie T, Hariz MI. Surgical management of Parkinson's disease. Expert Rev. Neurother. 10(6), 903-914 (2010).
95. Deep-Brain Stimulation for Parkinson Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N. Engl. J. Med. 345(13), 956-963 (2001).
96. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov. Disord. 21(Suppl. 14), S290-S304 (2006). (Pubitemid 44028288)
97. Deuschl G, Herzog J, Kleiner-Fisman G, et al. Deep brain stimulation: postoperative issues. Mov. Disord. 21(Suppl. 14), S219-S237 (2006). (Pubitemid 44028283)
98. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 362(22), 2077-2091 (2010).
99. Lane EL, Bjorklund A, Dunnett SB, Winkler C. Neural grafting in Parkinson's disease unraveling the mechanisms underlying graft-induced dyskinesia. Prog. Brain Res. 184, 295-309 (2010).
100. Hudson JL, Hoffman A, Stromberg I, Hoffer BJ, Moorhead JW. Allogeneic grafts of fetal dopamine neurons: behavioral indices of immunological interactions. Neurosci. Lett. 171(1-2), 32-36 (1994). (Pubitemid 24142082)
101. Piccini P, Pavese N, Hagell P, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128(Pt 12), 2977-2986 (2005). (Pubitemid 41746650)
102. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5(7), 627-628 (2002). (Pubitemid 34742975)
103. Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov. Disord. 26(11), 1997-2003 (2011).
104. Richardson RM, Freed CR, Shimamoto SA, Starr PA. Pallidal neuronal discharge in Parkinson's disease following intraputamenal fetal mesencephalic allograft. J. Neurol. Neurosurg. Psychiatry 82(3), 266-271 (2011).
105. Colosimo C, Martinez-Martin P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov. Disord. 25(9), 1131-1142 (2010).
106. Goetz CG, Nutt JG, Stebbins GT. The unified dyskinesia rating scale: presentation and clinimetric profile. Mov. Disord. 23(16), 2398-2403 (2008).
107. Goetz CG, Stebbins GT, Theeuwes A, et al. Temporal stability of the Unified Dyskinesia Rating Scale. Mov. Disord. 26(14), 2556-2559 (2011).
108. Schultz W. Multiple dopamine functions at different time courses. Annu. Rev. Neurosci. 30, 259-288 (2007). (Pubitemid 47218758)
109. Goetz CG, Wuu J, Mcdermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov. Disord. 23(5), 690-699 (2008).
110. De La Fuente-Fernandez R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol. 1(2), 85-91 (2002). (Pubitemid 37163493)